360 One Wam Limited (BOM:542772)
India · Delayed Price · Currency is INR 1,043.95
-21.00 (-1.97%)
At close: Aug 8, 2025
Inozyme Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 10,153 | 8,042 | 6,579 | 5,777 | 3,692 | Upgrade |
Depreciation & Amortization | - | 705.3 | 471.1 | 393.1 | 344.2 | 359.24 | Upgrade |
Other Amortization | - | - | 95.3 | 70 | 73.2 | 70.46 | Upgrade |
Loss (Gain) From Sale of Assets | - | -0.3 | -0.4 | -0.1 | -1.4 | 1.56 | Upgrade |
Loss (Gain) From Sale of Investments | - | -8,606 | -7,391 | -2,672 | -4,777 | -4,115 | Upgrade |
Stock-Based Compensation | - | 1,016 | 498.9 | 249.5 | 303.8 | 454.06 | Upgrade |
Provision & Write-off of Bad Debts | - | 31.1 | -0.1 | 7.9 | -16.5 | 13.88 | Upgrade |
Other Operating Activities | - | 287.2 | 1,172 | -4,106 | 2,375 | 2,423 | Upgrade |
Change in Other Net Operating Assets | - | -8,162 | 6,704 | -3,896 | 7,764 | 2,114 | Upgrade |
Operating Cash Flow | - | -24,109 | -4,701 | -13,225 | 9,288 | 4,627 | Upgrade |
Operating Cash Flow Growth | - | - | - | - | 100.75% | -71.58% | Upgrade |
Capital Expenditures | - | -552.4 | -1,021 | -729.9 | -163.8 | -252.18 | Upgrade |
Sale of Property, Plant & Equipment | - | 81.4 | 9.9 | 0.1 | - | - | Upgrade |
Cash Acquisitions | - | -821.1 | -45.1 | -367.8 | - | -2,258 | Upgrade |
Investment in Securities | - | -9,673 | -14,895 | 8,650 | -11,224 | 43,669 | Upgrade |
Other Investing Activities | - | 289.3 | 205.3 | 214.1 | 106.8 | 124.6 | Upgrade |
Investing Cash Flow | - | -10,676 | -15,746 | 7,766 | -11,281 | 41,284 | Upgrade |
Short-Term Debt Issued | - | 15,890 | 12,825 | 7,725 | 12,962 | - | Upgrade |
Long-Term Debt Issued | - | 20,265 | 28,847 | 31,838 | 11,785 | 13,668 | Upgrade |
Total Debt Issued | - | 36,155 | 41,672 | 39,563 | 24,748 | 13,668 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | - | -23,511 | Upgrade |
Long-Term Debt Repaid | - | -19,499 | -16,034 | -27,284 | -17,384 | -32,556 | Upgrade |
Total Debt Repaid | - | -19,499 | -16,034 | -27,284 | -17,384 | -56,067 | Upgrade |
Net Debt Issued (Repaid) | - | 16,656 | 25,638 | 12,279 | 7,364 | -42,399 | Upgrade |
Issuance of Common Stock | - | 24,725 | 661.1 | 219.9 | 518 | 341.44 | Upgrade |
Common Dividends Paid | - | -2,167 | -5,900 | -6,131 | -4,858 | -2,634 | Upgrade |
Other Financing Activities | - | -1,479 | -621 | -811.6 | -511.5 | -172.79 | Upgrade |
Financing Cash Flow | - | 37,735 | 19,777 | 5,556 | 2,512 | -48,356 | Upgrade |
Foreign Exchange Rate Adjustments | - | 24.4 | 2 | 112.5 | - | - | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | - | - | - | 0.11 | Upgrade |
Net Cash Flow | - | 2,975 | -667.5 | 209.2 | 519.2 | -2,446 | Upgrade |
Free Cash Flow | - | -24,661 | -5,722 | -13,955 | 9,124 | 4,374 | Upgrade |
Free Cash Flow Growth | - | - | - | - | 108.58% | -71.53% | Upgrade |
Free Cash Flow Margin | - | -66.93% | -19.58% | -67.84% | 44.01% | 26.44% | Upgrade |
Free Cash Flow Per Share | - | -63.35 | -15.55 | -38.44 | 25.31 | 12.37 | Upgrade |
Cash Interest Paid | - | 9,687 | 5,389 | 7,261 | 4,310 | 3,270 | Upgrade |
Cash Income Tax Paid | - | 3,055 | 2,641 | 2,343 | 2,035 | 1,160 | Upgrade |
Levered Free Cash Flow | - | 11,827 | -25,105 | 2,056 | 6,520 | -5,471 | Upgrade |
Unlevered Free Cash Flow | - | 17,371 | -21,140 | 4,503 | 8,789 | -2,932 | Upgrade |
Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.